Yong Xu

8PUBLICATIONS
13CO-AUTHORS
Toxicology (incl. clinical toxicology)Predictive and prognostic markersTraditional Chinese medicine and treatmentsCheminformatics and quantitative structure-activity relationshipsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 16, 2024
Identification of potential mechanisms of Schisandrin B in the treatment of idiopathic pulmonary fibrosis by integrating network pharmacology and experimental validation.

Tingyu Pan, Jieyu Wu, Xirui Qiu

|Feb 28, 2024
Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.

De-Yu Li, Xin Liu, Jing-Yi Huang

|Feb 24, 2023
Could patients with chronic obstructive pulmonary disease benefit from renin angiotensin system inhibitors? A meta-analysis.

Hongzhen Lv, Jingyi Huang, Miao Miao

|Oct 10, 2022
Sanzi Yangqin Decoction Alleviates Allergic Asthma by Modulating Th1/Th2 Balance: Coupling Network Pharmacology with Biochemical Pharmacology.

Wenpan Peng, Yong Xu, Yunhai Zhou

|Oct 21, 2021
Material Basis and Mechanism of Chansu Injection for COVID-19 Treatment Based on Network Pharmacology and Molecular Docking Technology.

Yong Xu, Wenpan Peng, Di Han

|Sep 02, 2021
Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC.

Wenpan Peng, Yong Xu, Fanchao Feng

Pageof 2

Frequent Collaborators

4 joint publications

Xianmei Zhou

3 joint publications

Wenpan Peng

2 joint publications

Qi Wu

1 joint publications

Ke-Jia Zhang